Condition: Diffuse Large B Cell Lymphoma · Sponsor: Sun Yat-sen University
This is a prospective, single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of selinexor in combination with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) followed by selinexor maintenance for untreated TP53-mutated diffuse large B-cell lymphoma (DLBCL) patients.
This description comes directly from the study's public registry record.
QingQing Cai, MD. PhD. · 0086-20-87342823 · caiqq@sysucc.org.cn
Yi Xia, MD. PhD. · 0086-20-87342823 · xiayi@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun yat-sen university cancer center | Guangzhou, Guangdong, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06517511